Bioactivity Comments |
Patent WO2004083247 A1 which claims tregalizumab, does not provide any affinity values for tregalizumab-CD4 binding, but does contain experimental evidence of the antibody's in vitro and in vivo biological effects [4]. |
Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|